Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing CoHKSE:03759 -2.03%90 PS Ratio is 3.05 as of Sep. 05, 2026, which is 55% below its 10-year median of 6.82. GuruFocus rates HKSE:03759 with a GF Score™ of 90/100 and a GF Value™ of HK$23.41 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 936 Biotechnology companies, Pharmaron Beijing Co ranks better than 67.63% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pharmaron Beijing Co's share price is HK$29.00.
Pharmaron Beijing Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was HK$9.50. Hence, Pharmaron Beijing Co's PS Ratio for today is 3.05.
The historical rank and industry rank for Pharmaron Beijing Co's PS Ratio or its related term are showing as below:
HKSE:03759'
s PS Ratio Range Over the Past 10 Years
Min: 2.74 Med: 6.82 Max: 30.09
Current: 4.87
During the past 12 years, Pharmaron Beijing Co's highest PS Ratio was 30.09. The lowest was 2.74. And the median was 6.82.
HKSE:03759's PS Ratio is ranked better than 67.63% of 936
companies
in the Biotechnology industry
Industry Median: 9.515
vs HKSE:03759: 4.87
Pharmaron Beijing Co Ltd has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Pharmaron Beijing Co was 14.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 21.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 16.00% per year.
During the past 12 years, Pharmaron Beijing Co's highest 3-Year average Revenue per Share Growth Rate was 31.80% per year. The lowest was -17.00% per year. And the median was 19.95% per year.
Pharmaron Beijing Co (HKSE:03759) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Pharmaron Beijing Co PS Ratio Related Terms
Pharmaron Beijing Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03759 vs VRTX, REGN, MRNA: PS Ratio Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Pharmaron Beijing Co's Share Price of today is HK$29.00. Pharmaron Beijing Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$9.50.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Pharmaron Beijing Co (HKSE:03759) has a PS Ratio of 3.05 as of Sep. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pharmaron Beijing Co and its competitors. This is 55% below median its historical median of 6.82. Over the past decade, Pharmaron Beijing Co's PS Ratio has ranged from 2.74 to 30.09. According to the industry distribution chart, Pharmaron Beijing Co ranks #303 out of 936 companies in the Biotechnology industry, placing it in the top 32.4%.
Is Pharmaron Beijing Co's PS Ratio too high?
Pharmaron Beijing Co's current PS Ratio of 3.05 is 55% below median its 10-year median of 6.82. Over the past 10 years, this metric has ranged from a low of 2.74 to a high of 30.09. The Biotechnology industry median PS Ratio is 9.52. Pharmaron Beijing Co's value of 3.05 is 67.9% below this industry median. Based on the distribution chart, Pharmaron Beijing Co ranks #303 out of 936 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #303 out of 936 companies for PS Ratio. This puts Pharmaron Beijing Co in the upper half of its industry. The industry median PS Ratio is 9.52. Pharmaron Beijing Co's value of 3.05 is 67.9% below this benchmark. Historically, Pharmaron Beijing Co's own PS Ratio has ranged from 2.74 to 30.09 over the past decade. While the company's 10-year median is 6.82 vs. the industry median of 9.52, Pharmaron Beijing Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaron Beijing Co's current PS Ratio of 3.05 is 67.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pharmaron Beijing Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current PS Ratio is 3.05, which is 55% below median its own 10-year median of 6.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$23.41, compared to a current price of HK$29.00 — trading 23.9% above its estimated fair value. The current PS Ratio is 3.05, which is 55% below median its 10-year median of 6.82 and 67.9% below the Biotechnology industry median of 9.52. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current PS Ratio is 3.05 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of HK$29.00 is trading 23.9% above its estimated GF Value™ of HK$23.41.
GuruFocus considers Pharmaron Beijing Co to be Modestly Overvalued.
Key valuation signals for HKSE:03759:
PS Ratio: 3.05 (55% below median its 10-year median of 6.82)
GF Value™: HK$23.41 vs. price of HK$29.00 (23.9% above fair value)
Industry Position: 67.9% below the Biotechnology median (#303 of 936)
No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score
Get the complete analysis for HKSE:03759
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03759 has been successfully added to your 
